Thomas O. Carpenter

Thomas O. Carpenter has been a member of the Clinical Advisory Board at Inozyme Pharma since October 2020. Prior to that, they served as the Head of Rare Renal and Musculoskeletal Diseases Research at Sanofi Genzyme from April 2015 to October 2020. From April 2010 to March 2015, they were the Principal Scientist/Associate Director at Genzyme, A Sanofi Company, where they directed scientific activities of ~40 FTEs across multiple functional groups (proteomics, biologics, translational sciences, histology and pathology, pharmacology). Thomas also validated a pre-clinical mouse model with a collaborator for rare genetic lung disease, pulmonary alveolar microlithiasis (PAM), and identified biomarkers and novel strategies for the treatment of PAM. Prior to their work at Genzyme, Dr. Carpenter served as an Instructor in Medicine at Massachusetts General Hospital/Harvard Medical School from September 2005 to November 2005. Thomas began their career as a Staff II Scientist at Genzyme Corporation from November 2005 to March 2010.

Thomas O. Carpenter has a PhD in Biology from McGill University, an MSc in Microbiology and Immunology from Université Laval, and a BSc in Biochemistry from McGill University.